Research
Hormonal
The review focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of anti-obesity drug discovery.
Practitioners should consider the role of GLP-1 RAs in developing new anti-obesity therapies.
StrongSupportsmedium confidence
This review examines AI's potential in developing next-generation anti-obesity therapeutics, with a focus on glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Why this rating
The abstract indicates a detailed examination of GLP-1 RAs in the context of AI and drug discovery.
Source
Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics
Amit Gangwal et al. · Drug Discovery Today · 2025
DOI 10.1016/j.drudis.2025.104333
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →